Table of Contents — Dec 2011 - 8th International Symposium on Advanced Ovarian Cancer: Optimal Therapy 4 Mar 2011, Valencia Spain

Blogger's Note: abstracts - subscription req'd ($$$) to access full view symposium articles

1. R. C. Bast, Jr Molecular approaches to personalizing management of ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii5-viii15 doi:10.1093/annonc/mdr516 
2. N. Urban Designing early detection programs for ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii6-viii18 doi:10.1093/annonc/mdr472 
3. N. F. Hacker Quality control in ovarian cancer surgery Ann Oncol (2011) 22(Suppl 8): viii19-viii22 doi:10.1093/annonc/mdr517 S. 
4. Kang and S.-Y. Park To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii23-viii28 doi:10.1093/annonc/mdr530 
5. N. Katsumata Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor Ann Oncol (2011) 22(Suppl 8): viii29-viii32 doi:10.1093/annonc/mdr468 
6. M. E. L. van der Burg, I. A. Boere, and P. M. J. J. Berns Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra Ann Oncol (2011) 22(Suppl 8): viii33-viii39 doi:10.1093/annonc/mdr514 
7. S. Pignata, L. Cannella, D. Leopardo, G. S. Bruni, G. Facchini, and C. Pisano Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up Ann Oncol (2011) 22(Suppl 8): viii40-viii44 doi:10.1093/annonc/mdr470 
8. G. J. S. Rustin Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed Ann Oncol (2011) 22(Suppl 8): viii45-viii48 doi:10.1093/annonc/mdr471 
9. E. A. Eisenhauer Optimal assessment of response in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii49-viii51 doi:10.1093/annonc/mdr467 
10. Michael A. Bookman Update of randomized trials in first-line treatment Ann Oncol (2011) 22(Suppl 8): Viii52-viii60 doi:10.1093/annonc/mdr466 
11. E. Pujade-Lauraine and J. Alexandre Update of randomized trials in recurrent disease Ann Oncol (2011) 22(Suppl 8): viii61-viii64 doi:10.1093/annonc/mdr518 
12. R. A. Burger Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii65-viii68 doi:10.1093/annonc/mdr529 
13. M. Markman The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy Ann Oncol (2011) 22(Suppl 8): viii69-viii71 doi:10.1093/annonc/mdr469 
14. C. Sessa Update on PARP1 inhibitors in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii72-viii76 doi:10.1093/annonc/mdr528 K. 
15. Bell-McGuinn, J. Konner, W. Tew, and D. R. Spriggs New drugs for ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii77-viii82 doi:10.1093/annonc/mdr531

8th Symposium on Advanced Ovarian Cancer 2011 (Spain) - GEICO - ESMO - European Society for Medical Oncology

It is a great honor and privilege for us to present you this 8th International Symposium on Advanced Ovarian Cancer: Optimal Therapy. Update, organized since 2009 in partnership between the Spanish Ovarian Cancer Research Group (GEICO) and the European Society for Medical Oncology.

This comprehensive multidisciplinary symposium covers all of the hot and innovative topics surrounding the diagnosis, biology, and therapy of ovarian cancer. In fact our meeting has grown to be recognized internationally as a classical educational event, offering a platform for many of you to gather, to teach, to learn, and also to discuss both the value and the methodology of how standard, as well as new approaches are being incorporated into the management of ovarian cancer.

More than 350 participants from all over the world attended the last edition of the meeting in 2009. It will be a pleasure to welcome all of you on 4th March 2011 in Valencia. Please reserve the date today!

On behalf of the Organizing Committee,

Andrés Poveda & Jan B Vermorken
Symposium Directors

For further information, please visit: www.doctaforum.com/aocsymp

The Probability Of Surviving Nine Types Of Cancer Is Analyzed - media item (Spain)